An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia

Clinical trial NCT00171249 · COMPLETED

Trial details

NCT number: NCT00171249
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Philadelphia Positive Chronic Myeloid Leukemia Acute Lymphoblastic Leukemia Acute Myeloid Leukemia

Start date: 1999-08-09
Primary completion: 2013-09-23
Enrollment: 293

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.